Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
September 10, 2025Scientific ReportsOpen Access

MCP-1-CCR2-M2 macrophages axis contributes to diffuse large B-cell lymphoma progression and inhibits antitumor immune response

View Full Paper
Ask AI
Bookmark
Share

Authors

ZWZhao-Feng WenQHQi-Tang HuangYWYangyang Wang

Discussion

Loading...

Member takes

Overview

Investigating the impact of MCP-1 and CCR2 blockade on immune response and DLBCL progression.

Key Points

  • Blocking the MCP-1/CCR2 axis significantly hinders DLBCL tumor growth and improves immune response.
  • Prognostic markers MCP-1, CD68, and CD163 are expressed in patients with diffuse large B-cell lymphoma.
  • Macrophage polarization was mimicked in vitro, showing the important role of the MCP-1/CCR2 axis.
  • CCR2 antagonist intervention reduced monocyte recruitment, affecting macrophage function in tumors.

Cite This Study

Wen et al. (2025) studied this question.

synapsesocial.com/papers/68c24236b210217d647a2c84https://doi.org/10.1038/s41598-025-14527-6
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1Preclinical evaluation of macrophage reprogramming in treatment of CTCL2025
  2. 2Cutaneous diffuse large B-cell lymphoma induce a macrophage immunosuppressive phenotype through IL-10 secretion2025
  3. 3Myeloid landscape profiling identifies DLBCL-specific suppressive macrophages colocalized with blood endothelial cells2025 · 5 citations
  4. 4Multistep molecular trajectory during monocytic myeloid-derived suppressor cell induction by diffuse large B-cell lymphoma cells2025
  5. 5IL-17–Induced CD70 expression promotes T-cell suppression in DLBCL: Implications for immune escape and T-cell exhaustion2025